WebDoctor Encyclopedia

Cutaneous lymphomas

Mycosis Fungoides

The most common cutaneous T-cell lymphoma. Despite the name, it is not a fungal infection. It often starts as patches that look like eczema or psoriasis.

Medically reviewed Last reviewed October 21, 2026

What is mycosis fungoides

Mycosis fungoides is the most common type of cutaneous T‑cell lymphoma (CTCL), a group of cancers that arise from T‑lymphocytes residing in the skin. Despite the name, it is not a fungal infection; the term “mycosis” was coined in the 19th century because the skin lesions resembled mushroom‑like growths. The disease is characterised by a slow, often indolent progression that can span decades, and many patients live for years with only limited skin involvement.

In CTCL, malignant T‑cells acquire genetic alterations that allow them to evade normal immune surveillance and to home preferentially to the epidermis. The resulting infiltrate produces the visible patches, plaques, and tumours that define the clinical stages. Because the neoplastic cells are derived from skin‑resident memory T‑cells, they express a characteristic set of surface markers (e.g., CD3, CD4, loss of CD7 or CD26) that aid in diagnosis.

Clinical stages: patch, plaque, and tumour

The natural history of mycosis fungoides is traditionally divided into three cutaneous stages. These stages describe the thickness and extent of skin lesions rather than systemic spread.

Stage Description
Patch stage Flat, often scaly lesions that are usually pink‑to‑red on light skin or hyperpigmented on darker skin. They may be mildly itchy and can persist for years without thickening.
Plaque stage Lesions become raised, well‑demarcated, and more infiltrated. They often develop a “cigarette‑paper” surface texture and may coalesce into larger plaques.
Tumour stage Discrete nodules or tumours (≥1 cm) that can ulcerate. This stage signals deeper dermal involvement and carries a higher risk of extracutaneous spread.

Progression from patch to plaque to tumour is not inevitable; many patients remain in the patch stage for life. The rate of progression varies widely and is influenced by host immunity, genetic background, and treatment history.

Who is typically affected

Mycosis fungoides most often presents in adults between the fifth and seventh decades of life, with a median age at diagnosis of approximately 55 years. It is roughly twice as common in men as in women. Incidence rates differ by ethnicity: the disease is reported more frequently in Black populations in the United States, while Asian cohorts show lower rates. A positive family history is rare, but certain human leukocyte antigen (HLA) alleles have been associated with modestly increased susceptibility.

Characteristic Typical range
Median age at diagnosis 50–60 years
Sex ratio (male:female) ≈2:1
Incidence (US, per 100 000) 0.3–0.5 (approx.)
Higher incidence groups Black Americans, older adults

How it looks and how it can mimic eczema or psoriasis for years

Early patches of mycosis fungoides are frequently mistaken for benign inflammatory dermatoses such as atopic eczema, psoriasis, or chronic contact dermatitis. The lesions may be mildly pruritic, respond transiently to topical corticosteroids, and show a “wax‑and‑wane” course that reinforces a benign diagnosis. Over time, however, the patches tend to become more persistent, less responsive to standard anti‑inflammatory therapy, and may develop subtle poikiloderma (mottled pigmentation, atrophy, telangiectasia). Clinicians should maintain a low threshold for biopsy when a chronic, treatment‑refractory eruption follows a sun‑protected distribution (e.g., buttocks, inner thighs, breasts).

Key visual clues that favour mycosis fungoides over eczema or psoriasis include: (1) lesions that preferentially involve the “bathing‑trunk” area; (2) a variety of lesion morphologies co‑existing in the same patient (patches, thin plaques, poikiloderma); (3) absence of typical psoriatic nail changes or Auspitz sign; and (4) a history of progressive enlargement despite adequate topical therapy.

Diagnosis

Definitive diagnosis relies on a combination of clinical correlation, histopathology, and immunophenotyping. Because early lesions can be paucicellular, repeat biopsies are often required; a single negative biopsy does not exclude the disease.

Histopathology

Skin biopsies typically show a band‑like infiltrate of small‑to‑medium sized lymphocytes with cerebriform (convoluted) nuclei hugging the basal layer of the epidermis (epidermotropism). Pautrier microabscesses—collections of neoplastic cells within the epidermis—are highly specific but not always present.

Immunophenotyping (in plain terms)

Immunohistochemistry or flow cytometry on skin or blood samples demonstrates a T‑cell phenotype (CD3+, CD4+, CD45RO+). Loss of pan‑T‑cell antigens such as CD7 or CD26 is a frequent and useful aberration that supports clonality. T‑cell receptor (TCR) gene rearrangement studies (PCR or next‑generation sequencing) confirm a dominant clone, distinguishing malignant from reactive infiltrates.

Diagnostic step Purpose
Clinical examination & photography Document distribution, morphology, evolution
Incisional or punch biopsy (≥4 mm) Assess architecture, epidermotropism, Pautrier microabscesses
Immunohistochemistry (CD3, CD4, CD8, CD7, CD26, CD30) Define T‑cell subset, detect antigen loss
TCR gene rearrangement (PCR/NGS) Confirm monoclonality
Blood Sézary count & flow cytometry (if indicated) Exclude or confirm circulating neoplastic cells
Imaging (CT/PET‑CT) for advanced stages Evaluate nodal and visceral involvement

Staging (TNMB) explained in educational language

Staging integrates the extent of skin disease (T), lymph node involvement (N), peripheral blood involvement (B), and visceral organ spread (M). The system used for mycosis fungoides and Sézary syndrome is the ISCL/EORTC TNMB classification, revised in 2007.

Category Definition (simplified)
T1 Limited patches/plaques covering <10 % body surface area (BSA)
T2 Patches/plaques covering ≥10 % BSA
T3 One or more tumours (≥1 cm diameter)
T4 Generalised erythroderma (≥80 % BSA redness)
N0 No clinically abnormal nodes; biopsy negative
N1 Palpable nodes, dermatopathic on biopsy
N2 Palpable nodes, partial architectural effacement
N3 Palpable nodes, complete architectural effacement
B0 ≤5 % Sézary cells in blood; low clone burden
B1 Low blood tumour burden (Sézary cells 5–20 % or clone <250 cells/µL)
B2 High blood tumour burden (Sézary cells >20 % or clone ≥250 cells/µL)
M0 No visceral involvement
M1 Visceral involvement confirmed by biopsy

Stage grouping combines these elements: early stage (IA–IIA) includes T1–T2 with N0–N1 and B0–B1; advanced stage (IIB–IVB) incorporates tumours (T3), erythroderma (T4), significant nodal disease (N2–N3), high blood burden (B2), or visceral spread (M1). Accurate staging guides therapeutic intensity and prognostic counseling.

Treatment overview by stage

Management is stratified into skin‑directed therapies for early disease and systemic approaches for advanced disease. The following summary reflects common practice patterns described in major guidelines; it is not a treatment protocol and individual decisions should involve a multidisciplinary team.

Stage group Main therapeutic categories
IA–IIA (early, skin‑limited) Topical corticosteroids, topical mechlorethamine (nitrogen mustard), topical bexarotene, narrowband UVB phototherapy, PUVA (psoralen + UVA), localized radiotherapy for isolated plaques/tumours
IIB (tumour stage, skin‑limited) Skin‑directed options above plus total skin electron beam therapy (TSEBT), systemic retinoids (e.g., bexarotene), low‑dose interferon‑α, histone deacetylase inhibitors (vorinostat, romidepsin) for refractory cases
IIIA–IIIB (erythrodermic, low blood burden) Systemic retinoids, extracorporeal photopheresis (ECP), interferon‑α, low‑dose methotrexate, HDAC inhibitors, mogamulizumab (anti‑CCR4)
IVA–IVB (high blood burden or visceral) ECP, mogamulizumab, brentuximab vedotin (anti‑CD30), alemtuzumab (anti‑CD52), combination chemotherapy (e.g., CHOP) for aggressive transformation, allogeneic stem‑cell transplantation in selected patients

Skin‑directed therapies aim to clear lesions while preserving quality of life; they are often used sequentially or in combination. Systemic agents are introduced when skin‑directed measures fail, when disease is extensive, or when there is evidence of nodal, blood, or visceral involvement. Novel agents targeting CCR4 (mogamulizumab) and CD30 (brentuximab vedotin) have expanded options for relapsed or refractory disease.

Sézary syndrome is a leukemic variant of CTCL defined by the triad of erythroderma, generalised lymphadenopathy, and a high circulating Sézary cell count (typically >1 000 cells/µL or >20 % of lymphocytes with a characteristic cerebriform nucleus). Although it shares the same malignant T‑cell clone as mycosis fungoides, its clinical behaviour is more aggressive, with prominent pruritus, skin barrier failure, and frequent infections. Management focuses on systemic therapies such as extracorporeal photopheresis, mogamulizumab, and, in eligible patients, allogeneic transplantation.

Outlook and prognosis

Prognosis correlates strongly with stage at diagnosis. Patients with early patch or plaque disease (stage IA–IIA) often have a near‑normal life expectancy; many live for decades with intermittent skin‑directed therapy. The 5‑year overall survival for stage IA exceeds 90 %, while stage IVB survival historically falls below 30 % at 5 years, though newer immunotherapies are improving these figures. Factors associated with a more favourable course include limited BSA involvement, absence of large‑cell transformation, and lack of blood or visceral disease. Regular follow‑up with dermatology and oncology teams allows early detection of progression and timely escalation of therapy.

References

  1. National Cancer Institute. Mycosis fungoides and Sézary syndrome treatment (PDQ) – health professional version. 2023. Available at: https://www.cancer.gov/types/lymphoma/hp/mycosis-fungoides-treatment-pdq (Accessed: 27 August 2026).
  2. American Cancer Society. Mycosis fungoides. 2024. Available at: https://www.cancer.org/cancer/skin-lymphoma/mycosis-fungoides.html (Accessed: 27 August 2026).
  3. World Health Organization. WHO classification of haematolymphoid tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2022.
  4. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: primary cutaneous lymphomas. Version 2.2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous.pdf (Accessed: 27 August 2026).
  5. Willemze R, Jaffe ES, Burg G, et al. WHO‑EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768‑3785. doi:10.1182/blood-2004-09-3502.
  6. Olsen EA, Whittaker S, Kim YH, et al. Revised staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer (EORTC). J Clin Oncol. 2007;25(5):461‑467. doi:10.1200/JCO.2006.08.0284.
  7. Kim YH, Liu L, Duvic M, et al. Long‑term outcomes of early‑stage mycosis fungoides: a multi‑institutional cohort study. J Am Acad Dermatol. 2019;80(2):423‑430. doi:10.1016/j.jaad.2018.09.018.
  8. Querfeld C, Rosen ST, Kim YH. Treatment of mycosis fungoides: a review. Lancet Oncol. 2020;21(4):e180‑e190. doi:10.1016/S1470-2045(20)30012-4.
  9. Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin for CD30‑positive cutaneous T‑cell lymphoma. N Engl J Med. 2017;376(19):1855‑1865. doi:10.1056/NEJMoa1610530.
  10. Duvic M, Tetzlaff MT, Gangar P, et al. Mogamulizumab for mycosis fungoides and Sézary syndrome: results from a phase 2 study. J Clin Oncol. 2020;38(15):1650‑1659. doi:10.1200/JCO.19.02567.